Article
On-demand use of a phosphodiesterase type-5 inhibitor did not affect prostatic or urinary outcomes of therapy for BPH, a post hoc analysis of a large randomized trial showed.
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.